Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
31/07/26	US$6.180	+4.04%	191,793
30/07/26	US$5.940	+5.13%	175,465
29/07/26	US$5.650	-5.36%	174,453
28/07/26	US$5.970	+2.40%	164,102
27/07/26	US$5.830	+1.92%	202,328

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 21:00:00 31/07/2026 BST			5-day change	1st Jan Change
6.180 ^USD	+4.04%		+8.04%	-70.57%

07-27	Certain Ordinary Shares of Regencell Bioscience Holdings Limited are subject to a Lock-Up Agreement Ending on 27-JUL-2026.	CI
05-08	Regencell Bioscience Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2025	CI

Market Cap	3.02B 2.62B 2.44B 2.24B 4.23B 288B 4.3B 28.78B 11.29B 143B 11.33B 11.08B 481B	P/E 2024	-10.2x	P/E 2025	-2,351x
Enterprise Value	3.01B 2.62B 2.44B 2.24B 4.23B 288B 4.29B 28.74B 11.28B 143B 11.32B 11.07B 480B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	11.62%	Yield 2024 *	-	Yield 2025	-

07-27	Certain Ordinary Shares of Regencell Bioscience Holdings Limited are subject to a Lock-Up Agreement Ending on 27-JUL-2026.	CI
05-08	Regencell Bioscience Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2025	CI
31/10/25	Regencell Bioscience Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2025	CI
30/10/25	Regencell Bioscience Holdings Limited Auditor Raises 'Going Concern' Doubt	CI
22/09/25	Regencell Bioscience Holdings Limited(NasdaqCM:RGC) added to S&P Global BMI Index	CI
30/06/25	Regencell Bioscience Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2024	CI
30/06/25	Regencell Bioscience Holdings Limited Announces Board Changes, Effective June 30, 2025	CI
25/06/25	Top Premarket Gainers	MT
23/06/25	Top Premarket Decliners	MT
20/06/25	Top Premarket Decliners	MT
18/06/25	Top Premarket Decliners	MT
17/06/25	Top Premarket Gainers	MT
17/06/25	Regencell Bioscience Extends Gains Pre-Bell Tuesday Following 276% Surge Monday	MT

06-16	RGC SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026	NE
06-16	RGC Holzer & Holzer, LLC Reminds Investors of the June 23, 2026 Lead Plaintiff Deadline in the Regencell Bioscience Holdings Limited Securities Class Action	NE
06-15	RGC Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026	NE
06-11	RGC SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026	NE
06-10	RGC INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Deadline on June 23, 2026	NE

Regencell Bioscience Holdings Limited Share Price

Stocks

RGC

KYG7487R1002

Biotechnology & Medical Research

Valuation: Regencell Bioscience Holdings Limited

Chart: Regencell Bioscience Holdings Limited

Latest news : Regencell Bioscience Holdings Limited

Analysts' recommendations: Regencell Bioscience Holdings Limited

Press Releases: Regencell Bioscience Holdings Limited

News in other languages: Regencell Bioscience Holdings Limited

Quotes and Performance

Course Extremes

Managers and Directors: Regencell Bioscience Holdings Limited

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

27/06/25	El milagro de las hierbas : esta acción sube un 20.000% en un año sin vender nada
18/02/22	La formule liquide expérimentale RGC-COV19TM de Regencell Bioscience a démontré son efficacité, chez ses patients recrutés, dans l'élimination des symptômes légers à modérés de la COVID-19 au cours d'une période de traitement de...
17/02/22	La formulazione liquida sperimentale RGC-COV19TM di Regencell Bioscience si dimostra efficace nell'eliminazione dei sintomi di COVID-19 da lievi a moderati nei pazienti arruolati nello studio di efficacia EARTH, in un periodo di trattamento di 6...
17/02/22	Flüssigprüfformel RGC-COV19TM von Regencell Bioscience zeigt Wirksamkeit bei den rekrutierten Patienten in der Wirksamkeitsstudie EARTH und behebt leichte bis mäßige COVID-19-Symptome innerhalb von 6 Tagen
17/02/22	Ensayo de eficacia EARTH: la fórmula líquida en investigación RGC-COV19TM de Regencell Bioscience demuestra eficacia en los pacientes inscritos al eliminar los síntomas leves o moderados de la COVID-19 en un período de tratamiento de seis días

1 day	+4.04%
1 week	+8.04%
1 month	+1.48%
3 months	-78.85%
6 months	-75.27%
Current year	-70.57%

1 week	5.33	6.35
1 month	4.51	8.2
Current year	4.51	69
1 year	4.51	69
3 years	0.08	83.6
5 years	0.08	83.6
10 years	0.08	83.6

Manager	Title	Age	Since
Yat-Gai Au CEO	Chief Executive Officer	54	31/12/2013
Wai Hong Chung COO	Chief Operating Officer	49	31/07/2021
Yat-Pui Au PRN	Corporate Officer/Principal	52	31/01/2023

Director	Title	Age	Since
Wai Hong Chung BRD	Director/Board Member	49	27/12/2023
Yee Wah Hui BRD	Director/Board Member	54	30/06/2021
Wing Yan Lo BRD	Director/Board Member	65	12/12/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
REGENCELL BIOSCIENCE HOLDINGS LIMITED	+4.04%	+8.04%	-53.18%	+1,157.89%	3.04B
LONZA GROUP AG	-1.40%	+2.59%	-1.71%	+11.28%	48.53B
REVOLUTION MEDICINES, INC.	-2.41%	-0.90%	+403.17%	+614.40%	39.87B
IQVIA HOLDINGS INC.	-1.16%	+12.96%	+26.45%	+5.03%	38.68B
BEONE MEDICINES AG	-1.88%	-3.03%	+4.94%	+47.52%	35.13B
CELLTRION, INC.	-1.74%	+5.12%	+9.58%	+46.02%	29.79B
ASCENDIS PHARMA A/S	-2.85%	-3.92%	-	-	16.08B
MEDPACE HOLDINGS, INC.	-0.21%	-4.04%	+35.09%	+127.95%	16.11B
EUROFINS SCIENTIFIC SE	-0.64%	+2.65%	+1.25%	+8.92%	13.61B
ICON PUBLIC LIMITED COMPANY	-1.19%	-1.32%	-3.32%	-34.94%	12.62B
Average	-0.94%	+1.75%	+46.92%	+220.45%	25.35B
Weighted average by Cap.	-1.53%	+2.11%	+75.20%	+141.27%

	2024	2025
Net sales	-	-
Net income	-4.3M -3.74M -3.48M -3.2M -6.03M -411M -6.13M -41.03M -16.1M -204M -16.16M -15.8M -686M	-3.58M -3.12M -2.9M -2.66M -5.03M -342M -5.11M -34.18M -13.42M -170M -13.46M -13.17M -571M
Net Debt	-7.88M -6.85M -6.37M -5.85M -11.05M -752M -11.22M -75.11M -29.48M -374M -29.58M -28.93M -1.26B	-4.35M -3.78M -3.52M -3.23M -6.11M -416M -6.2M -41.51M -16.29M -207M -16.35M -15.99M -694M